X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Henlius will be responsible for clinical development, manufacturing and supply upon launch of specific formulation of HANSIZHUANG (serplulimab injection), Henlius' novel anti-PD-1 mAb.
Lead Product(s): Serplulimab,Fluorouracil
Therapeutic Area: Oncology Product Name: Hansizhuang
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Intas Pharmaceuticals
Deal Size: $195.5 million Upfront Cash: $44.4 million
Deal Type: Collaboration October 27, 2023
Details:
Hansizhuang (serplulimab) is a novel humanized monoclonal anti-PD-1 antibody, which is approved for the first-line treatment of extensive stage small cell lung cancer in combination with carboplatin and etoposide.
Lead Product(s): Serplulimab,Carboplatin,Etoposide
Therapeutic Area: Oncology Product Name: Hansizhuang
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
Results from both groups (group A, n=20; group B, n=21) demonstrated that Hansizhuang (serplulimab) plus HLX04 was safe and well-tolerated. As assessed by IRRC, the ORR was 30.0% (95% CI, 11.9–54.3) in group A and 14.3% (95% CI, 3.0–36.3) in group B.
Lead Product(s): Serplulimab,Bevacizumab
Therapeutic Area: Oncology Product Name: Hansizhuang
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
The study results demonstrated that HLX10 (serplulimab) in combination with chemotherapy can significantly extend median OS to 15.4 months when compared to control group in first-line SCLC, gaining global recognition while leapfrogging immunotherapy treatment for SCLC.
Lead Product(s): Serplulimab,Carboplatin
Therapeutic Area: Oncology Product Name: HLX10
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Henlius will release 4 study results of 2 products to be commercialized, the novel anti-PD-1 mAb serplulimab and the bevacizumab biosimilar HLX04 used in patients with advanced hepatocellular carcinoma. Serplulimab injection is anti-PD-1 mAb for treatment of solid tumours.
Lead Product(s): Serplulimab
Therapeutic Area: Oncology Product Name: HLX10
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2021
Details:
Chiome agreed to grant Henlius an exclusive right and license to antibodies targeting human TROP2 and related intellectual property rights to research, develop, manufacture and commercialize the Licensed Products in China.
Lead Product(s): LIV-2008
Therapeutic Area: Oncology Product Name: LIV-2008
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Chiome Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 14, 2021
Details:
Pursuant to the Agreement, Essex and Henlius will co-develop the bevacizumab HLX04 for treatment of ophthalmic diseases such as exudative (wet) Age-related Macular Degeneration (wAMD).
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: HLX04
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Essex Biotechnology
Deal Size: $25.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement October 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
